- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02244736
Vascular Markers During OGTT in Diabetics and First-degree Relatives
Changes of the Endothelial Glycocalyx, the Elastic Properties of the Arteries and the Coronary Flow Reserve (CFR) During Oral Glucose Tolerance Test in Patients With New Onset Diabetes Mellitus and First-degree Relatives
Descripción general del estudio
Estado
Condiciones
Descripción detallada
The investigators plan to examine 90 subjects without known diabetes a standard 75-gr oral glucose tolerance test (OGTT) will be performed. [30 first degree relatives of diabetics with normal OGTT (relatives), 30 with normal OGTT and no family history of diabetes (normals), and 30 with abnormal OGTT (diabetics) matched for age and sex].
Plasma glucose and serum insulin levels will be measured in venous blood collected at 0, 30, 60, 90 and 120min after glucose loading. At the same time intervals, the investigators will measure:
- the carotid to femoral pulse wave velocity (PWVc) using the Complior apparatus
- the aortic pulse wave velocity (PWVa), central systolic blood pressure (cSBP) and augmentation index (AI) using an oscillometric method (Arteriograph,TensioMed) as markers of arterial stiffness and wave reflections
- the coronary flow reserve (CFR) at baseline and after adenosine infusion (140 μg × kg-1 × min-1) for 3 minutes to assess coronary vasomotor function
- the perfusion boundary region (PBR- micrometers) of the sublingual arterial microvessels (ranged from 5-25 micrometers) using Sideview Darkfield imaging (Microscan, Glycocheck). Increased PBR is considered an accurate non invasive index of reduced endothelial glycocalyx thickness.
In addition, the investigators will measure free fatty acids, triglycerides, glycerol, C reactive protein (CRP), transforming growth factor-b (TGF-b), Lipoprotein-Associated Phospholipase A2, (LP-LPA2), tumor necrosis factor (TNF-a), interleukin 6 (IL6) and interleukin 10 (IL10) propeptide of type I procollagen, (PIP), propeptide of procollagen type III (PIIINP), matrix metallopeptidases 9 and 2 (MMP 9 and 2), macrophage-colony stimulating factor ( MCSF).
The investigators will measure insulin resistance a) after fasting, using homeostatic model assessment (HOMA) and hepatic insulin sensitivity (HIS) b) during oral glucose tolerance test (OGTT) using Matsuda index and insulin sensitivity index (ISI). The investigators will categorize patients in those with normal (<140 mg/dl at 120 min) and those with abnormal OGTT (>200mg/dl at 120min).
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Attiki
-
Athens, Attiki, Grecia, 12462
- ''Attikon'' University General Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- subjects without known diabetes
- first degree relatives of diabetics
Exclusion Criteria:
- coronary or valvular heart disease
- congestive heart failure
- peripheral vascular disease
- liver or kidney failure
- history of alcohol or drug abuse
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
---|
Controls
Subjects with no family history of diabetes mellitus and normal OGTT
|
Relatives
First-degree relatives of patients with diabetes mellitus and normal OGTT
|
Diabetics
Subjects with abnormal OGTT
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Differences of vascular function at baseline and during OGTT among the 3 groups.
Periodo de tiempo: Baseline, 30 min, 60 min, 90 min, and 120 min during OGTT.
|
Differences of pulse wave velocity, augmentation index and central aortic blood pressure at baseline and during OGTT among the 3 groups.
|
Baseline, 30 min, 60 min, 90 min, and 120 min during OGTT.
|
Differences of endothelial function at baseline and during OGTT among the 3 groups.
Periodo de tiempo: Baseline, 30 min, 60 min, 90 min, and 120 min during OGTT.
|
Differences of coronary flow reserve and endothelial glycocalyx thickness at baseline and during OGTT among the 3 groups.
|
Baseline, 30 min, 60 min, 90 min, and 120 min during OGTT.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Insulin resistance and arterial stiffness
Periodo de tiempo: Baseline, 30 min, 60 min, 90 min, and 120 min during OGTT.
|
Association of insulin resistance with changes of pulse wave velocity, augmentation index and central aortic blood pressure during OGTT
|
Baseline, 30 min, 60 min, 90 min, and 120 min during OGTT.
|
Insulin resistance and endothelial function
Periodo de tiempo: Baseline, 30 min, 60 min, 90 min,120 min of OGTT
|
Association of insulin resistance with changes of coronary flow reserve and endothelial glycocalyx during OGTT
|
Baseline, 30 min, 60 min, 90 min,120 min of OGTT
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Vaia Lambadiari, MD, 2nd Department of Internal Medicine , University of Athens, Greece
- Investigador principal: Charalambos Koukoulis, MD, 2nd Cardiology Department, University of Athens, Greece
- Investigador principal: Maria Varoudi, MD, 2nd Cardiology Department, University of Athens, Greece
- Investigador principal: Vlasios Tritakis, MD, 2nd Cardiology Department, University of Athens, Greece
- Investigador principal: Helen Triantafyllidi, MD, 2nd Cardiology Department, University of Athens, Greece
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- K-DM-ATTIKON
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Diabetes mellitus
-
Meir Medical CenterTerminadoDiabetes mellitus tipo 2 | Diabetes Mellitus, No Insulino Dependiente | Diabetes Mellitus, sobre Tratamiento Hipoglucemiante Oral | Diabetes mellitus tipo adultoIsrael
-
Medical College of WisconsinMedical University of South CarolinaTerminadoDiabetes mellitus | Diabetes mellitus tipo 2 | Diabetes mellitus de inicio en adultos | Diabetes mellitus no insulinodependiente | Diabetes mellitus no insulinodependiente, tipo IIEstados Unidos
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.TerminadoDiabetes Mellitus, Tipo 1 | Diabetes tipo 1 | Diabetes tipo 1 | Diabetes mellitus tipo 1 | Diabetes autoinmune | Diabetes Mellitus, Insulino-Dependiente | Diabetes de inicio juvenil | Diabetes Autoinmune | Diabetes mellitus insulinodependiente 1 | Diabetes Mellitus, Insulino-Dependiente, 1 | Diabetes Mellitus... y otras condicionesEstados Unidos
-
SanofiTerminadoDiabetes Mellitus Tipo 1-Diabetes Mellitus Tipo 2Hungría, Federación Rusa, Alemania, Polonia, Japón, Estados Unidos, Finlandia
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and Digestive...Activo, no reclutandoDiabetes Mellitus, Tipo 2 | Diabetes Mellitus, Tipo II | Diabetes mellitus, inicio en adultos | Diabetes mellitus, no insulinodependiente | Diabetes Mellitus, No Insulino DependienteEstados Unidos
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)TerminadoDiabetes Mellitus, Tipo 2 | Diabetes Mellitus, Tipo II | Diabetes mellitus, inicio en adultos | Diabetes mellitus, no insulinodependiente | Diabetes Mellitus, No Insulino DependienteEstados Unidos
-
Guang NingReclutamientoDiabetes mellitus tipo 2 | Diabetes mellitus tipo 1 | Diabetes monogenética | Diabetes pancreatogénica | Diabetes mellitus inducida por fármacos | Otras formas de diabetes mellitusPorcelana
-
Hoffmann-La RocheRoche DiagnosticsTerminadoDiabetes Mellitus Tipo 2, Diabetes Mellitus Tipo 1Alemania
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)TerminadoDiabetes Mellitus, Tipo 2 | Diabetes Mellitus, Tipo II | Diabetes mellitus, inicio en adultos | Diabetes mellitus, no insulinodependiente | Diabetes Mellitus, No Insulino DependienteEstados Unidos
-
University of California, San FranciscoJuvenile Diabetes Research FoundationTerminadoDiabetes mellitus tipo 1 | Diabetes Mellitus, Tipo I | Diabetes mellitus insulinodependiente 1 | Diabetes Mellitus, Insulino-Dependiente, 1 | IDDMEstados Unidos, Australia